August/September 2012 NDF-RT (version name 2012.09.04)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on July 2012 NDF content (patch 328)
and full RxNorm release dated 8/6/2012.
TOTAL CONCEPTS IN PREVIOUS VERSION (2012.07.02.12AA): 47763
VA Product concepts added: 52
Generic concepts added: 11
Ingredient concepts added: 11
VA Drug Interaction concepts added: 266
New concepts manually added for current version: 28
TOTAL CONCEPTS IN CURRENT VERSION (2012.09.04.12AA): 48131
The 28 new concepts manually added for this release included 16 concepts
added to the Chemical/Ingredient hierarchy, 2 added to the Mechanism of
Action hierarchy, 2 added to the Physiologic Effect hierarchy, and 8 added
to FDA Established Pharmacologic Classes. In addition, the following concept
name changes occurred for this release: Allogeneic Cellularized Scaffold
[EPC] was changed to Allogeneic Cultured Cell Scaffold [EPC], Allogeneic
Cord Blood Hematopoietic Progenitor Cell [EPC] was changed to llogeneic Cord
Blood Hematopoietic Progenitor Cell Therapy [EPC], and Autologous Fibroblast
[EPC] was changed to Autologous Cultured Cell [EPC].
-----------------------------------------------------------------
July 2012 NDF-RT (version name 2012.07.02)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on May 2012 NDF content (patch 322)
and full RxNorm release dated 6/4/2012. This release also represents an
update of the Disease/Finding and Chemical/Ingredient hierarchies based on
MeSH Diseases and Chemicals (from the current version of MeSH available in
the 2012AA version of the UMLS Metathesaurus):
TOTAL CONCEPTS IN PREVIOUS VERSION (2012.06.04.11AB): 47378
VA Product concepts added: 19
Generic concepts added: 2
Ingredient concepts added: 1
VA Drug Interaction concepts added: 364
Obsolete RxNorm Dose Form concepts removed manually: 1
TOTAL CONCEPTS IN CURRENT VERSION (2012.07.02.12AA): 47763
No concept name changes occurred for this release.
-----------------------------------------------------------------
June 2012 NDF-RT (version name 2012.06.04)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on April 2012 NDF content (patch 319)
and full RxNorm release dated 5/7/2012.
TOTAL CONCEPTS IN PREVIOUS VERSION (2012.05.07.11AB): 47260
VA Product concepts added: 29
Generic concepts added: 2
Ingredient concepts added: 3
VA Drug Interaction concepts added: 83
RxNorm Dose Form concepts added: 1
TOTAL CONCEPTS IN CURRENT VERSION (2012.06.04.11AB): 47378
No concept name changes occurred for this release.
-----------------------------------------------------------------
May 2012 NDF-RT (version name 2012.05.07)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on March 2012 NDF content (patch 316)
and full RxNorm release dated 4/2/2012.
TOTAL CONCEPTS IN PREVIOUS VERSION (2012.04.02.11AB): 47075
VA Product concepts added: 25
Generic concepts added: 2
Ingredient concepts added: 5
VA Drug Interaction concepts added: 139
New concepts manually added for current version: 14
TOTAL CONCEPTS IN CURRENT VERSION (2012.05.07.11AB): 47260
The 14 new concepts manually added for this release included 8 added to the
Chemical/Ingredient hierarchy, 1 added to the Physiologic Effect hierarchy,
and 5 added to FDA Established Pharmacologic Classes. No concept name changes
occurred for this release.
-----------------------------------------------------------------
April 2012 NDF-RT (version name 2012.04.02)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on February 2012 NDF content
(patch 313) and full RxNorm release dated 3/5/2012.
TOTAL CONCEPTS IN PREVIOUS VERSION (2012.03.05.11AB): 46922
VA Product concepts added: 17
Generic concepts added: 1
Ingredient concepts added: 33
VA Drug Interaction concepts added: 79
New concepts manually added for current version: 35
Concepts programmatically removed for current version: 12
TOTAL CONCEPTS IN CURRENT VERSION (2012.04.02.11AB): 47075
The 35 new concepts manually added for this release included 1 added to the
Chemical/Ingredient hierarchy, 8 added to the Mechanism of Action hierarchy,
9 added to the Physiologic Effect hierarchy, and 17 added to FDA Established
Pharmacologic Classes. No concept name changes occurred for this release.
Effective this release, the Status property has been removed. Status
information for any VA NDF-sourced concept is captured from each IEN record
for that concept and is now represented by one of four possible qualifier
values on the existing VANDF_Record property: Active/Master, Inactive/Master,
Active, or Inactive. Multiple VANDF_Record properties may exist in a
concept, one per IEN record. For more information, please refer to the
section entitled Concept Properties in the revised35NDF-RT Documentation
file included with this release.
-----------------------------------------------------------------
March 2012 NDF-RT (version name 2012.03.05)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on January 2012 NDF content
(patch 310) and full RxNorm release dated 2/6/2012.
TOTAL CONCEPTS IN PREVIOUS VERSION (2012.02.06.11AB): 46790
VA Product concepts added: 27
Ingredient concepts added: 3
VA Drug Interaction concepts added: 94
New concepts manually added for current version: 8
Concepts manually removed for current version: 1
TOTAL CONCEPTS IN CURRENT VERSION (2012.03.05.11AB): 46922
The 8 new concepts manually added for this release included 5 added to the
Mechanism of Action hierarchy, and 3 added to FDA Established Pharmacologic
Classes. The one concept retired for this release was Gas [Dose Form]. No
concept name changes occurred for this release.
-----------------------------------------------------------------
February 2012 NDF-RT (version name 2012.02.06)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on December 2011 NDF content
(patch 307) and full RxNorm release dated 1/3/2012.
TOTAL CONCEPTS IN PREVIOUS VERSION (2012.01.03.11AB): 46665
VA Product concepts added: 41
Generic concepts added: 6
Ingredient concepts added: 6
VA Drug Interaction concepts added: 34
New concepts manually added for current version: 38
TOTAL CONCEPTS IN CURRENT VERSION (2012.02.06.11AB): 46790
The 38 new concepts manually added for this release included 3 added to the
PE hierarchy, 2 added to the Chemical/Ingredient hierarchy, and 33 added to
FDA Established Pharmacologic Classes. No concept name changes occurred for
this release.
-----------------------------------------------------------------
December 2011/January 2012 NDF-RT (version name 2012.01.03)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on November 2011 NDF content
(patch 304) and full RxNorm release dated 12/5/2011. This release also
represents an update of the Disease/Finding and Chemical/Ingredient
hierarchies based on MeSH Diseases and Chemicals (from the current version
of MeSH available in the 2011AB version of the UMLS Metathesaurus):
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.11.07.11AA): 46044
VA Product concepts added: 111
VA Drug Class concepts added: 1
Generic concepts added: 29
Ingredient concepts added: 11
VA Drug Interaction concepts added: 289
RxNorm Dose Form concepts added: 1
New Chemical/Ingredient concepts added from MeSH Chemicals: 101
New Disease/Finding concepts added from MeSH Diseases: 86
MeSH Diseases concepts programmatically removed: 1
MeSH Chemicals concepts programmatically removed: 12
New concepts manually added for current version: 5
TOTAL CONCEPTS IN CURRENT VERSION (2012.01.03.11AB): 46665
The 5 new concepts manually added for this release included 3 added to the PE
hierarchy, and 2 added to FDA Established Pharmacologic Classes. In addition,
the following concept name changes occurred for this release. Biological
Products [Chemical/Ingredient] was changed to Biological Agents
[Chemical/Ingredient]; Epoetin Alfa [Chemical/Ingredient] was changed to
epoetin alfa [Chemical/Ingredient]; Ferrosoferric Oxide [Chemical/Ingredient]
was changed to Ferumoxytol [Chemical/Ingredient]; Flexibacteraceae Infections
[Disease/Finding] was changed toCytophagaceae Infections [Disease/Finding];
Gas [Dose Form] was changed to Inhalant or Spray [Dose Form]; Gestational
Trophoblastic Neoplasms [Disease/Finding] was changed to Gestational
Trophoblastic Disease [Disease/Finding]; Indigotindisulfonate Sodium
[Chemical/Ingredient] was changed to Indigo Carmine [Chemical/Ingredient];
insulin aspart [Chemical/Ingredient]was changed to Insulin Aspart
[Chemical/Ingredient]; insulin LISPRO [Chemical/Ingredient]was changed to
Insulin Lispro [Chemical/Ingredient]; Insulin, NPH [Chemical/Ingredient]was
changed to Insulin, Isophane [Chemical/Ingredient]; Insulin, Protamine Zinc,
Beef-Pork [Chemical/Ingredient] was changed to insulin, protamine zinc,
beef-pork [Chemical/Ingredient]; Insulin, Regular, Beef-Pork
[Chemical/Ingredient] was changed to insulin, regular, beef-pork
[Chemical/Ingredient]; Interferon Alfa-2a [Chemical/Ingredient] was changed
to interferon alfa-2a [Chemical/Ingredient]; Interferon Alfa-2b
[Chemical/Ingredient] was changed to interferon alfa-2b
[Chemical/Ingredient];Interferon gamma-1b [Chemical/Ingredient] was changed
tointerferon gamma-1b [Chemical/Ingredient]; Intervertebral Disk Degeneration
[Disease/Finding] was changed to Intervertebral Disc Degeneration
[Disease/Finding]; Intervertebral Disk Displacement [Disease/Finding] was
changed to Intervertebral Disc Displacement [Disease/Finding]; Kangai-1
Protein [Chemical/Ingredient] was changed to Antigens, CD82
[Chemical/Ingredient]; LDL-Receptor Related Protein 1 [Chemical/Ingredient]
was changed to Low Density Lipoprotein Receptor-Related Protein-1
[Chemical/Ingredient]; LDL-Receptor Related Protein 2 [Chemical/Ingredient]
was changed to Low Density Lipoprotein Receptor-Related Protein-2
[Chemical/Ingredient]; Legg-Perthes Disease [Disease/Finding] was changed to
Legg-Calve-Perthes Disease [Disease/Finding]; lopinavir [Chemical/Ingredient]
was changed to Lopinavir [Chemical/Ingredient]; Mental Retardation
[Disease/Finding]was changed to Intellectual Disability [Disease/Finding];
Mycobacterium Infections, Atypical [Disease/Finding] was changed to
Mycobacterium Infections, Nontuberculous [Disease/Finding]; NADP
Transhydrogenase [Chemical/Ingredient] was changed to NADP Transhydrogenases
[Chemical/Ingredient]; NPH Insulin, Beef [Chemical/Ingredient] was changed to
isophane insulin, beef [Chemical/Ingredient]; NPH Insulin, Beef-Pork
[Chemical/Ingredient] was changed to isophane insulin, beef-pork
[Chemical/Ingredient]; NPH Insulin, Human [Chemical/Ingredient] was changed
to isophane insulin, human [Chemical/Ingredient]; NPH Insulin, Pork
[Chemical/Ingredient] was changed to isophane insulin, pork
[Chemical/Ingredient]; Regurgitation, Gastric [Disease/Finding] was changed
to Laryngopharyngeal Reflux [Disease/Finding]; Sarcoma, Ewing's
[Disease/Finding] was changed to Sarcoma, Ewing [Disease/Finding]; Tiapride
[Chemical/Ingredient] was changed to Tiapamil Hydrochloride
[Chemical/Ingredient]; Trenbolone [Chemical/Ingredient] was changed to
Trenbolone Acetate [Chemical/Ingredient]; and triptorelin pamoate
[Chemical/Ingredient] was changed to Triptorelin Pamoate
[Chemical/Ingredient].
-----------------------------------------------------------------
November 2011 NDF-RT (version name 2011.11.07)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed RxNorm data,
comprising the following changes based on full RxNorm release dated
10/3/2011.
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.10.03.11AA): 46044
TOTAL CONCEPTS IN CURRENT VERSION (2011.11.07.11AA): 46044
No concept name changes occurred for this release.
-----------------------------------------------------------------
October 2011 NDF-RT (version name 2011.10.03)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on August 2011 NDF content (patch 290)
and full RxNorm release dated 9/6/2011.
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.09.06.11AA): 45756
VA Product concepts added: 27
Generic concepts added: 4
Ingredient concepts added: 7
VA Drug Interaction concepts added: 242
New concepts manually added for current version: 8
TOTAL CONCEPTS IN CURRENT VERSION (2011.10.03.11AA): 46044
The 8 new concepts manually added for this release included 5 added to the
MoA hierarchy and 3 added to FDA Established Pharmacologic Classes. No
concept name changes occurred for this release.
-----------------------------------------------------------------
September 2011 NDF-RT (version name 2011.09.06)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on July 2011 NDF content (patch 287)
and full RxNorm release dated 8/1/2011.
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.08.01.11AA): 45625
VA Product concepts added: 34
Generic concepts added: 5
Ingredient concepts added: 7
VA Drug Interaction concepts added: 83
New concepts manually added for current version: 2
TOTAL CONCEPTS IN CURRENT VERSION (2011.09.06.11AA): 45756
The 2 new concepts manually added for this release included 1 added to the
PE hierarchy and 1 added to FDA Established Pharmacologic Classes. No concept
name changes occurred for this release.
-----------------------------------------------------------------
August 2011 NDF-RT (version name 2011.08.01)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on June 2011 NDF content (patch 284)
and full RxNorm release dated 7/5/2011.
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.07.05.11AA): 45523
VA Product concepts added: 28
Generic concepts added: 3
Ingredient concepts added: 12
VA Drug Interaction concepts added: 56
New concepts manually added for current version: 3
TOTAL CONCEPTS IN CURRENT VERSION (2011.08.01.11AA): 45625
The 3 new concepts manually added for this release included 2 added to the
MoA hierarchy and 1 added to FDA Established Pharmacologic Classes. No
concept name changes occurred for this release.
-----------------------------------------------------------------
July 2011 NDF-RT (version name 2011.07.05)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on May 2011 NDF content (patch 281)
and full RxNorm release dated 6/6/2011. This release also represents an
update of the Disease/Finding and Chemical/Ingredient hierarchies based on
MeSH Diseases and Chemicals (from the current version of MeSH available in
the 2011AA version of the UMLS Metathesaurus):
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.06.06.10AB): 45428
VA Product concepts added: 20
Generic concepts added: 2
Ingredient concepts added: 3
VA Drug Interaction concepts added: 62
New Disease/Finding concepts added from MeSH Diseases: 1
MeSH Diseases concepts programmatically removed: 1
New concepts manually added for current version: 8
TOTAL CONCEPTS IN CURRENT VERSION (2011.07.05.11AA): 45523
The 8 new concepts manually added for this release included 4 added to the
MoA hierarchy and 4 added to FDA Established Pharmacologic Classes. In
addition, the following concept name changes occurred for this release:
External Pharmacologic Classes was changed to FDA Established Pharmacologic
Classes, and Pediculocide [EPC] was changed to Pediculicide [EPC].
-----------------------------------------------------------------
June 2011 NDF-RT (version name 2011.06.06)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on April 2011 NDF content (patch 278)
and full RxNorm release dated 5/2/2011.
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.05.02.10AB): 45362
VA Product concepts added: 30
Ingredient concepts added: 3
VA Drug Interaction concepts added: 33
TOTAL CONCEPTS IN CURRENT VERSION (2011.06.06.10AB): 45428
No concept name changes occurred for this release.
-----------------------------------------------------------------
May 2011 NDF-RT (version name 2011.05.02)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on March 2011 NDF content (patch 275)
and full RxNorm release dated 4/4/2011.
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.04.04.10AB): 45235
VA Product concepts added: 37
Generic concepts added: 6
Ingredient concepts added: 8
VA Drug Interaction concepts added: 76
TOTAL CONCEPTS IN CURRENT VERSION (2011.05.02.10AB): 45362
No concept name changes occurred for this release.
-----------------------------------------------------------------
April 2011 NDF-RT (version name 2011.04.04)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on February 2011 NDF content
(patch 272) and full RxNorm release dated 3/7/2011.
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.03.07.10AB): 45197
VA Product concepts added: 19
Ingredient concepts added: 1
VA Drug Interaction concepts added: 18
TOTAL CONCEPTS IN CURRENT VERSION (2011.04.04.10AB): 45235
No concept name changes occurred for this release.
-----------------------------------------------------------------
March 2011 NDF-RT (version name 2011.03.07)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on January 2011 NDF content
(patch 269) and full RxNorm release dated 2/7/2011.
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.02.07.10AB): 45149
VA Product concepts added: 9
Generic concepts added: 1
Ingredient concepts added: 1
VA Drug Interaction concepts added: 37
TOTAL CONCEPTS IN CURRENT VERSION (2011.03.07.10AB): 45197
No concept name changes occurred for this release.
-----------------------------------------------------------------
February 2011 NDF-RT (version name 2011.02.07)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on December 2010 NDF content
(patch 266) and full RxNorm release dated 1/3/2011. This release also
represents a refresh of the Disease/Finding hierarchy based on MeSH Diseases
(from the current version of MeSH available in the 2010AB version of the
UMLS Metathesaurus):
TOTAL CONCEPTS IN PREVIOUS VERSION (2011.01.03.10AB): 44936
VA Product concepts added: 28
Generic concepts added: 7
Ingredient concepts added: 7
VA Drug Interaction concepts added: 58
New Disease/Finding concepts added from MeSH Diseases: 92
MeSH Diseases concepts programmatically removed: 4
New concepts manually added for current version: 25
TOTAL CONCEPTS IN CURRENT VERSION (2011.02.07.10AB): 45149
The 25 new concepts manually added for this release included 13 added to the
MoA hierarchy, 7 added to the PE hierarchy, and 5 added to External
Pharmacologic Classes. In addition, the following concept name changes
occurred for this release: Carbohydrate-Deficient Glycoprotein Syndrome
[Disease/Finding] was changed to Congenital Disorders of Glycosylation
[Disease/Finding], Cryopyrin-associated Periodic Syndromes [Disease/Finding]
was changed to Cryopyrin-Associated Periodic Syndromes [Disease/Finding],
Estrogen Receptor Inhibitor [EPC] was changed to Estrogen Receptor Antagonist
[EPC], Hermaphroditism, True [Disease/Finding] was changed to Ovotesticular
Disorders of Sex Development [Disease/Finding], Listeria Infections
[Disease/Finding] was changed to Listeriosis [Disease/Finding], Ovarian
Failure, Premature [Disease/Finding] was changed to Primary Ovarian
Insufficiency [Disease/Finding], Paget Disease Extramammary [Disease/Finding]
was changed to Paget Disease, Extramammary [Disease/Finding], and Sex
Differentiation Disorders [Disease/Finding] was changed to Disorders of Sex
Development [Disease/Finding].
-----------------------------------------------------------------
December 2010/January 2011 NDF-RT (version name 2011.01.03)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on November 2010 NDF content
(patch 259) and full RxNorm release dated 12/6/2010. This release also
represents a refresh of the Chemical/Ingredient hierarchy based on MeSH
Chemicals (from the current version of MeSH available in the 2010AB version
of the UMLS Metathesaurus):
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.11.01.10AA): 44620
VA Product concepts added: 57
Generic concepts added: 5
Ingredient concepts added: 17
VA Drug Interaction concepts added: 141
New Chemical/Ingredient concepts added from MeSH Chemicals: 93
MeSH Chemicals concepts programmatically removed: 8
New concepts manually added for current version: 11
TOTAL CONCEPTS IN CURRENT VERSION (2011.01.03.10AB): 44936
The 11 new concepts manually added for this release included 8 added to the
MoA hierarchy and 3 added to External Pharmacologic Classes. In addition,
the following concept name changes occurred for this release:
1-Phosphatidylinositol 3-Kinase [Chemical/Ingredient] was changed to
Phosphatidylinositol 3-Kinase [Chemical/Ingredient],
2-phenylbenzimidazole-5-sulfonic acid [Chemical/Ingredient] was changed to
ensulizole [Chemical/Ingredient], Amyloid beta-Protein [Chemical/Ingredient]
was changed to Amyloid beta-Peptides [Chemical/Ingredient], Antibodies,
Monoclonal, Murine-derived [Chemical/Ingredient] was changed to Antibodies,
Monoclonal, Murine-Derived [Chemical/Ingredient], Antigens, CD26
[Chemical/Ingredient] was changed to Dipeptidyl Peptidase 4
[Chemical/Ingredient], Antithrombins [Chemical/Ingredient] was changed to
Antithrombin Proteins [Chemical/Ingredient], Botulinum Toxin Type A
[Chemical/Ingredient] was changed to Botulinum Toxins, Type A
[Chemical/Ingredient], botulinum toxin type B [Chemical/Ingredient] was
changed to rimabotulinumtoxinB [Chemical/Ingredient], Carboxymethylcellulose
[Chemical/Ingredient] was changed to Carboxymethylcellulose Sodium
[Chemical/Ingredient], Chloroguanide [Chemical/Ingredient] was changed to
Proguanil [Chemical/Ingredient], Midodrine Monohydrochloride
[Chemical/Ingredient] was changed to Midodrine Hydrochloride
[Chemical/Ingredient], Nectar [Chemical/Ingredient] was changed to Plant
Nectar [Chemical/Ingredient], Orciprenaline [Chemical/Ingredient] was
changed to Metaproterenol [Chemical/Ingredient], Procetofen
[Chemical/Ingredient] was changed to Fenofibrate [Chemical/Ingredient],
Proteochondroitin Sulfates [Chemical/Ingredient] was changed to Chondroitin
Sulfate Proteoglycans [Chemical/Ingredient], silochrome [Chemical/Ingredient]
was changed to Silochrome [Chemical/Ingredient], Testosterone
5-alpha-Reductase [Chemical/Ingredient] was changed to 3-Oxo-5-alpha-Steroid
4-Dehydrogenase [Chemical/Ingredient], Thiopronine [Chemical/Ingredient] was
changed to Tiopronin [Chemical/Ingredient], Thyroid Extract, Desiccated
[Chemical/Ingredient] was changed to Thyroid (USP) [Chemical/Ingredient],
Toothpaste [Chemical/Ingredient] was changed to Toothpastes
[Chemical/Ingredient], and Triethylenetetramine [Chemical/Ingredient] was
changed to Trientine [Chemical/Ingredient].
-----------------------------------------------------------------
November 2010 NDF-RT (version name 2010.11.01)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on October 2010 NDF content
(patch 253) and full RxNorm release dated 10/4/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.10.04.10AA): 44462
VA Product concepts added: 94
Generic concepts added: 11
Ingredient concepts added: 15
VA Drug Interaction concepts added: 38
TOTAL CONCEPTS IN CURRENT VERSION (2010.11.01.10AA): 44620
No concept name changes occurred for this release.
-----------------------------------------------------------------
October 2010 NDF-RT (version name 2010.10.04)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on September 2010 NDF content
(patch 250) and full RxNorm release dated 9/7/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.09.07.10AA): 44337
VA Product concepts added: 27
Generic concepts added: 4
Ingredient concepts added: 3
VA Drug Interaction concepts added: 91
TOTAL CONCEPTS IN CURRENT VERSION (2010.10.04.10AA): 44462
No concept name changes occurred for this release.
-----------------------------------------------------------------
September 2010 NDF-RT (version name 2010.09.07)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on August 2010 NDF content (patch 247)
and full RxNorm release dated 8/2/2010. This release also represents a
refresh of the Disease/Finding hierarchy based on MeSH Diseases (from the
current version of MeSH available in the 2010AA version of the
UMLS Metathesaurus):
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.08.02.10AA): 43855
VA Product concepts added: 50
Generic concepts added: 3
Ingredient concepts added: 7
VA Drug Interaction concepts added: 164
New Disease/Finding concepts added from MeSH Diseases refresh: 294
MeSH Diseases concepts programmatically removed: 48
New concepts manually added for current version: 12
TOTAL CONCEPTS IN CURRENT VERSION (2010.09.07.10AA): 44337
The 12 concepts manually added for this version included were all added to
the MoA hierarchy. There were also a number of manual name changes made for
this release: Absorbs Ultraviolet A Radiation [MoA] was changed to
Ultraviolet A Radiation Absorption [MoA], Absorbs Ultraviolet B Radiation
[MoA] was changed to Ultraviolet A Radiation Absorption [MoA], Adjuvants,
Immunologic [MoA] was changed to Immunologic Adjuvants [MoA], Age categories
[Disease/Finding] was changed to Age Categories [Disease/Finding],
Antithrombin III Activators [MoA] was changed to Antithrombin 3 Activators
[MoA], beta Tubulin Interaction [MoA] was changed to beta Tubulin
Interactions [MoA], Bone Surface Interaction [MoA] was changed to Bone
Surface Interactions [MoA], COX-2 Inhibitors [MoA] was changed to
Cyclooxygenase 2 Inhibitors [MoA], Current Non-Smoker [Disease/Finding] was
changed to Current Non-smoker [Disease/Finding], Decreased Calcium-Sensing
Receptor Sensitivity [MoA] was changed to Decreased Calcium-sensing Receptor
Sensitivity [MoA], Elderly adult [Disease/Finding] was changed to Elderly
Adult [Disease/Finding], Female gender [Disease/Finding] was changed to
Female Gender [Disease/Finding], Free Radical Scavenging [MoA] was changed
to Free Radical Scavenging Activity [MoA], Glucagon Receptor Interaction
[MoA] was changed to Glucagon Receptor Interactions [MoA], Histamine
Antagonists [MoA] was changed to Histamine Receptor Antagonists [MoA],
Histamine H1 Antagonists [MoA] was changed to Histamine H1 Receptor
Antagonists [MoA], Histamine H2 Antagonists [MoA] was changed to Histamine H2
Receptor Antagonists [MoA], Increased Calcium-Sensing Receptor Sensitivity
[MoA] was changed to Increased Calcium-sensing Receptor Sensitivity [MoA],
Male gender [Disease/Finding] was changed to Male Gender [Disease/Finding],
Middle aged adult [Disease/Finding] was changed to Middle Aged Adult
[Disease/Finding], Older child [Disease/Finding] was changed to Older Child
[Disease/Finding], Peroxisome Proliferator-Activated Receptor Activity [MoA]
was changed to Peroxisome Proliferator-activated Receptor Activity [MoA],
Peroxisome Proliferator-Activated Receptor alpha Agonists [MoA] was changed
to Peroxisome Proliferator-activated Receptor alpha Agonists [MoA],
Peroxisome Proliferator-Activated Receptor beta Agonists [MoA] was changed
to Peroxisome Proliferator-activated Receptor beta Agonists [MoA],
Peroxisome Proliferator-Activated Receptor delta Agonists [MoA] was changed
to Peroxisome Proliferator-activated Receptor delta Agonists [MoA],
Peroxisome Proliferator-Activated Receptor gamma Agonists [MoA] was changed
to Peroxisome Proliferator-activated Receptor gamma Agonists [MoA],
Platelet-Derived Growth Factor alpha Receptor Inhibitors [MoA] was changed to
Platelet-derived Growth Factor alpha Receptor Inhibitors [MoA],
Platelet-Derived Growth Factor alpha Receptor Interactions [MoA] was changed
to Platelet-derived Growth Factor alpha Receptor Interactions [MoA],
Platelet-Derived Growth Factor beta Receptor Inhibitors [MoA] was changed to
Platelet-derived Growth Factor beta Receptor Inhibitors [MoA],
Platelet-Derived Growth Factor beta Receptor Interactions [MoA] was changed
to Platelet-derived Growth Factor beta Receptor Interactions [MoA],
Platelet-Derived Growth Factor Receptor Inhibitors [MoA] was changed to
Platelet-derived Growth Factor Receptor Inhibitors [MoA], Preterm infant
[Disease/Finding] was changed to Preterm Infant [Disease/Finding], Receptor
Activity Modifying Proteins Antagonists [MoA] was changed to Receptor
Activity Modifying Protein Antagonists, Tubulin Interaction [MoA] was changed
to Tubulin Interactions [MoA], Tumor Necrosis Factor Alpha Receptor Blocking
Activity [MoA] was changed to Tumor Necrosis Factor alpha Receptor Blocking
Activity [MoA], Tumor Necrosis Factor Beta Receptor Blocking Activity [MoA]
was changed to Tumor Necrosis Factor beta Receptor Blocking Activity, Viral
Envelope Interaction [MoA] was changed to Viral Envelope Interactions [MoA],
Young adult [Disease/Finding] was changed to Young Adult [Disease/Finding],
and Young child [Disease/Finding] was changed to Young Child
[Disease/Finding].
-----------------------------------------------------------------
August 2010 NDF-RT (version name 2010.08.02)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on July 2010 NDF content (patch 244)
and full RxNorm release dated 7/6/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.07.06.10AA): 43816
VA Product concepts added: 12
Generic concepts added: 2
Ingredient concepts added: 2
VA Drug Interaction concepts added: 23
TOTAL CONCEPTS IN CURRENT VERSION (2010.08.02.10AA): 43855
No concept name changes occurred for this release.
-----------------------------------------------------------------
July 2010 NDF-RT (version name 2010.07.06)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on June 2010 NDF content (patch 241)
and full RxNorm release dated 6/7/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.06.07.10AA): 43789
VA Product concepts added: 18
Generic concepts added: 3
Ingredient concepts added: 5
VA Drug Interaction concepts added: 1
TOTAL CONCEPTS IN CURRENT VERSION (2010.07.06.10AA): 43816
There were 4 manual concept name changes this month: Autonomic Ganglionic
Blockers [EPC] was changed to Autonomic Ganglionic Blocker [EPC],
Electrolytes [EPC] was changed to Electrolyte [EPC], Human Immunodeficiency
Virus 1 Non-Nucleoside and Nucleoside Analog Reverse Transcriptase Inhibitors
[EPC] was changed to Human Immunodeficiency Virus 1 Non-Nucleoside and
Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], and Locally acting
Aminosalicylate [EPC] was changed to Locally-acting Aminosalicylate [EPC].
-----------------------------------------------------------------
June 2010 NDF-RT (version name 2010.06.07)
NDF-RT is now published on the first Monday of each month to coincide with
the release date of RxNorm. This will better ensure that RxNorm_CUI and
RxNorm_Name property values will remain up-to-date and in sync with monthly
RxNorm content.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on May 2010 NDF content (patch 238)
and full RxNorm release dated 5/3/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.04.13.9AB): 43706
VA Product concepts added: 18
Generic concepts added: 3
Ingredient concepts added: 4
VA Drug Interaction concepts added: 51
New concepts manually added for current version: 7
TOTAL CONCEPTS IN CURRENT VERSION (2010.06.07.10AA): 43789
The 7 concepts manually added for this version included were all added to
External Pharmacologic Classes. There were also 2 manual concept name changes
this month: Insulin Analogue [EPC] was changed to Insulin Analog [EPC], and
Prostaglandin Analogue [EPC] was changed to Prostaglandin Analog [EPC]. Other
concept name changes were derived programmatically from this month's
refreshed MeSH Chemicals content.
-----------------------------------------------------------------
April 2010 NDF-RT (version name 2010.04.13)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on April 2010 NDF content (patch 235)
and full RxNorm release dated 4/5/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.03.09.9AB): 43483
VA Product concepts added: 20
Generic concepts added: 1
Ingredient concepts added: 5
VA Drug Interaction concepts added: 197
TOTAL CONCEPTS IN CURRENT VERSION (2010.04.13.9AB): 43706
No concept name changes occurred for this release.
-----------------------------------------------------------------
March 2010 NDF-RT (version name 2010.03.09)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on March 2010 NDF content (patch 232)
and full RxNorm release dated 3/1/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.02.09.9AB): 43414
VA Product concepts added: 29
Generic concepts added: 3
Ingredient concepts added: 2
VA Drug Interaction concepts added: 35
TOTAL CONCEPTS IN CURRENT VERSION (2010.03.09.9AB): 43483
There were two manual concept name changes for this release: E3 Ubiquitin
Ligase Inhibitor [MoA] was changed to E3 Ubiquitin Ligase Inhibitors [MoA],
and Para-Aminobenzoic Acid Inhibitor [MoA] was changed to Para-Aminobenzoic
Acid Inhibitors [MoA].
-----------------------------------------------------------------
February 2010 NDF-RT (version name 2010.02.09)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on February 2010 NDF content
(patch 228) and full RxNorm release dated 2/1/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2010.01.12.9AB): 43285
VA Product concepts added: 11
Generic concepts added: 1
Ingredient concepts added: 1
VA Drug Interaction concepts added: 116
TOTAL CONCEPTS IN CURRENT VERSION (2010.02.09.9AB): 43414
One manual concept name change occurred this month. L-Calcium Channel
Receptor Antagonists[MoA] was changed to L-Calcium Channel Receptor
Antagonists [MoA].
-----------------------------------------------------------------
December 2009/January 2010 NDF-RT (version name 2010.01.12)
This release reflects content in a new NDF-RT namespace, which is intended
to be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on January 2010 NDF content
(patch 225) and full RxNorm release dated 1/4/2010:
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.11.10.9AB): 43147
VA Product concepts added: 67
Generic concepts added: 4
Ingredient concepts added: 19
VA Drug Interaction concepts added: 45
New concepts manually added for current version: 3
TOTAL CONCEPTS IN CURRENT VERSION (2010.01.12.9AB): 43285
The 3 concepts manually added for this version included were all added to
External Pharmacologic Classes. A number of manual concept name changes also
occurred this month, fixing pluralization and capitalization inconsistencies:
14-alpha demethylase Inhibitors [MoA] was changed to 14-alpha Demethylase
Inhibitors [MoA], ADH Receptor Antagonist [MoA] was changed to ADH Receptor
Antagonists [MoA], AMPA Receptor Antagonist [MoA] was changed to AMPA
Receptor Antagonists [MoA], Amylin Agonist [MoA] was changed to Amylin
Agonists [MoA], Antidiuretic Hormone Antagonist [MoA] was changed to
Antidiuretic Hormone Antagonists [MoA], Catecholamine-depleting
Sympatholytics [EPC] was changed to Catecholamine-depleting Sympatholytic
[EPC], decreased fibroblast migration [PE] was changed to Decreased
Fibroblast Migration [PE], decreased polymorphonuclear leukocyte migration
[PE] was changed to Decreased Polymorphonuclear Leukocyte Migration [PE],
Glucagon-like Peptide-1 (GLP-1) Agonist [MoA] was changed to Glucagon-like
Peptide-1 (GLP-1) Agonists [MoA], Glucagon-like Peptide-1 (GLP-1) Antagonist
[MoA] was changed to Glucagon-like Peptide-1 (GLP-1) Antagonists [MoA],
Hypothalamic Hormone Receptor Agonist [MoA] was changed to Hypothalamic
Hormone Receptor Agonists [MoA], Hypothalamic Hormone Receptor Antagonist
[MoA] was changed to Hypothalamic Hormone Receptor Antagonists [MoA],
increased fibroblast migration [PE] was changed to Increased Fibroblast
Migration [PE], Increased polymorphonuclear leukocyte migration [PE] was
changed to Increased Polymorphonuclear Leukocyte Migration [PE], increased
Urethra Smooth Muscle Tone [PE] was changed to Increased Urethra Smooth
Muscle Tone [PE], Inhalation Diagnostic Agents [EPC] was changed to
Inhalation Diagnostic Agent [EPC], Ionotropic Glutamate Receptor Antagonist
[MoA] was changed to Ionotropic Glutamate Receptor Antagonists [MoA], Kainate
Receptor Antagonist [MoA] was changed to Kainate Receptor Antagonists [MoA],
Keratinocyte Growth Factor Receptor Agonist [MoA] was changed to Keratinocyte
Growth Factor Receptor Agonists [MoA], Keratinocyte Growth Factor Receptor
Antagonist [MoA] was changed to Keratinocyte Growth Factor Receptor
Antagonists [MoA], L-Calcium Channel Receptor Antagonist [MoA] was changed to
L-Calcium Channel Receptor Antagonists[MoA], N-Calcium Channel Receptor
Antagonist [MoA] was changed to N-Calcium Channel Receptor Antagonists [MoA],
Receptor Activity Modifying Protein Agonist [MoA] was changed to Receptor
Activity Modifying Protein Agonists [MoA], Receptor Activity Modifying
Proteins Antagonist [MoA] was changed to Receptor Activity Modifying Proteins
Antagonists [MoA], T-Calcium Channel Receptor Antagonist [MoA] was changed to
T-Calcium Channel Receptor Antagonists [MoA], and Voltage-gated Calcium
Channel Receptor Antagonist [MoA] was changed to Voltage-gated Calcium
Channel Receptor Antagonists [MoA].
-----------------------------------------------------------------
November 2009 NDF-RT (version name 2009.11.10)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed RxNorm, UMLS CUI, and
MeSH Chemicals data, comprising the following changes based on the full
RxNorm release dated 11/2/2009, and MeSH/UMLS CUI content extracted from UMLS
version 2009AB (released in November 2009):
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.10.13.9AA): 43050
MeSH Chemicals concepts added: 98
New concepts manually added for current version: 10
MeSH Chemicals concepts programmatically removed: 7
Concepts manually removed for current version: 4
TOTAL CONCEPTS IN CURRENT VERSION (2009.11.10.9AB): 43147
The 10 concepts manually added for this version included 10 added to External
Pharmacologic Classes. Several manual concept name changes also occurred this
month: M2 Proton Pump Inhibitor [EPC] was changed to Influenza A M2 Protein
Inhibitor [EPC], and Melanocyte Pigment Inhibitor [EPC] was changed to
Melanin Synthesis Inhibitor [EPC]. Other concept name changes were derived
programmatically from this month's refreshed MeSH Chemicals content.
-----------------------------------------------------------------
October 2009 NDF-RT (version name 2009.10.13)
This release reflects content in a new NDF-RT namespace, which is intended
to be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF, RxNorm, and UMLS
CUI data, comprising the following changes based on October 2009 NDF content
(patch 216), full RxNorm release dated 10/5/2009, and UMLS CUI content
extracted from UMLS version 2009AA (released in April 2009):
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.09.08.9AA): 42671
VA Product concepts added: 96
Generic concepts added: 8
Ingredient concepts added: 25
VA Drug Interaction concepts added: 250
TOTAL CONCEPTS IN CURRENT VERSION (2009.10.13.9AA): 43050
Concept name changes in this version were derived programmatically from this
month's refreshed NDF content.
-----------------------------------------------------------------
August/September 2009 NDF-RT (version name 2009.09.08)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF, RxNorm, and MeSH
Chemicals data, comprising the following changes based on August 2009 NDF
content (patch 210), full RxNorm release dated 9/8/2009, and MeSH content
extracted from UMLS version 2009AA (released in April 2009):
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.07.14.9AA): 41363
VA Product concepts added: 39
Generic concepts added: 8
Ingredient concepts added: 19
VA Drug Interaction concepts added: 11
RxNorm Dose Form concepts added: 1
MeSH Chemicals concepts added: 1244
New concepts manually added for current version: 4
MeSH Chemicals concepts programmatically removed: 16
Concepts manually removed for current version: 2
TOTAL CONCEPTS IN CURRENT VERSION (2009.09.08.9AA): 42671
The 4 concepts manually added for this version included 3 added to the PE
hierarchy, and 1 added to External Pharmacologic Classes.
For this version, all concepts under External Pharmacologic Classes
(totaling 409), formerly containing the tag [EXT] appended to the concept
name, have been changed by replacing the [EXT] tag with [EPC]. Other concept
name changes were derived programmatically from this month's refreshed MeSH
and NDF content.
-----------------------------------------------------------------
July 2009 NDF-RT (version name 2009.07.14)
This release reflects content in a new NDF-RT namespace, which is intended
to be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on July 2009 NDF content (patch 207)
and full RxNorm release dated 7/6/2009:
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.06.09.9AA): 41299
VA Product concepts added: 50
Generic concepts added: 5
Ingredient concepts added: 9
TOTAL CONCEPTS IN CURRENT VERSION (2009.07.14.9AA): 41363
There were 2 concept name changes this month: HYDROMORPHONE 0.2MG/ML INJ,30ML
[VA Product] was changed to HYDROMORPHONE HCL 0.2MG/ML INJ,30ML [VA Product],
and MYCOPHENOLATE MOFETIL HYDROCHLORIDE 500MG/VIL INJ,IV [VA Product] was
changed to MYCOPHENOLATE MOFETIL HYDROCHLORIDE 500MG/VIL INJ [VA Product].
-----------------------------------------------------------------
June 2009 NDF-RT (version name 2009.06.09)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on May 2009 NDF content (patch 204)
and full RxNorm release dated 6/1/2009:
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.05.12.9AA): 41255
VA Product concepts added: 21
VA Drug Interaction concepts added: 2
Generic concepts added: 2
Ingredient concepts added: 3
RxNorm Dose Form concepts added: 5
New concepts manually added for current version: 11
TOTAL CONCEPTS IN CURRENT VERSION (2009.06.09.9AA): 41299
There were 27 concept name changes this month. All concepts in the
Therapeutic Uses [Therapeutic Intent] hierarchy, added for the May release,
were renamed, with [TC] replacing the former [Therapeutic Intent] tag
appended to each concept name. The top-level concept in this hierarchy,
Therapeutic Uses [Therapeutic Intent], was renamed to Therapeutic Categories
[TC]. Any concepts in NDF-RT with a role pointing to a concept in this
hierarchy will now show the name of this role as "has_TC", replacing the
former "has_Therapeutic_Intent".
The 11 new concepts manually added for this release included 1 added to the
MoA hierarchy, 7 added to the EXT hierarchy, and 3 added to the new
Therapeutic Categories [TC] hierarchy.
-----------------------------------------------------------------
May 2009 NDF-RT (version name 2009.05.12)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on April 2009 NDF content (patch 201)
and full RxNorm release dated 5/4/2009:
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.04.14.9AA): 41180
VA Product concepts added: 24
VA Drug Interaction concepts added: 4
Generic concepts added: 2
Ingredient concepts added: 4
New concepts manually added for current version: 41
TOTAL CONCEPTS IN CURRENT VERSION (2009.04.14.9AA): 41255
The 41 new concepts manually added for this release include the creation of
the new Therapeutic Uses [Therapeutic Intent] hierarchy. Concepts in this
hierarchy were added to provide has_Therapeutic_Intent mappings to a number
of EXT concepts containing therapeutic intent components. In addition to the
27 concepts in this hierarchy, manually added concepts for this month
included 2 added to the MoA hierarchy, 9 added to the PE hierarchy, 2 added
to the Chemical/Ingredient hierarchy, and 1 added to the EXT hierarchy.
There were 3 concept name changes this month: perflexane
[Chemical/Ingredient] was changed to perfluorohexane [Chemical/Ingredient];
Vascular Endothelial Growth Factor Receptor-directed Antibody Interactions
[MoA] was changed to Vascular Endothelial Growth Factor-directed Antibody
Interactions [MoA]; and Vascular Endothelial Growth Factor Receptor-directed
Antibody [EXT] was changed to Vascular Endothelial Growth Factor-directed
Antibody [EXT].
-----------------------------------------------------------------
April 2009 NDF-RT (version name 2009.04.14)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on March 2009 NDF content (patch 198)
and full RxNorm release dated 4/6/2009:
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.03.10.8AB): 40797
VA Product concepts added: 226
VA Drug Interaction concepts added: 96
Generic concepts added: 11
Ingredient concepts added: 40
Drug Class concepts added: 2
New concepts manually added for current version: 9
Concepts manually removed for this version: 1
TOTAL CONCEPTS IN CURRENT VERSION (2009.04.14.9AA): 41180
The 9 new concepts manually added for this release included 1 added to the
MoA hierarchy, 3 added to the Chemical/Ingredient hierarchy, and 5 added to
the EXT hierarchy.
The changed concepts count this month is due to 6 concept name changes:
Folic Acid Antagonists [MoA] was changed to Folic Acid Metabolism Inhibitors
[MoA]; Peroxisome Proliferator-Activated Receptor Alpha Activity [MoA] was
changed to Peroxisome Proliferator-Activated Receptor alpha Agonists [MoA];
Peroxisome Proliferator-Activated Receptor Beta Activity [MoA] was changed to
DPeroxisome Proliferator-Activated Receptor beta Agonists [MoA]; Peroxisome
Proliferator-Activated Receptor Delta Activity [MoA] was changed to
Peroxisome Proliferator-Activated Receptor delta Agonists [MoA]; Peroxisome
Proliferator-Activated Receptor Gamma Activity [MoA] was changed to
Peroxisome Proliferator-Activated Receptor gamma Agonists [MoA]; and
Peroxisome-proliferator Receptor Alpha Activator [EXT] was changed to
Peroxisome Proliferator Receptor alpha Agonist [EXT].
-----------------------------------------------------------------
March 2009 NDF-RT (version name 2009.03.10)
This release reflects content in a new NDF-RT namespace, which is intended
to be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
Content in this version of NDF-RT represents refreshed NDF and RxNorm data,
comprising the following changes based on September 2008 NDF content
(patch 179) and full RxNorm release dated 3/2/2009:
TOTAL CONCEPTS IN PREVIOUS VERSION (2009.02.10.8AB): 39140
VA Product concepts added: 1020
VA Drug Interaction concepts added: 613
Generic concepts added: 95
Ingredient concepts added: 181
RxNorm Dose Form concepts added: 7
Drug Class concepts added: 3
New concepts manually added for current version: 12
NDF-RT Dose Form concepts added: 9
Supply concepts deleted: 276
MoA concepts removed for this version: 6
PE concepts removed for this version: 1
TOTAL CONCEPTS IN CURRENT VERSION (2009.03.10.8AB): 40797
The 12 new concepts manually added for this release included 3 added to the
MoA hierarchy, 6 added to the PE hierarchy, and 3 added to the EXT hierarchy.
In addition to the changes noted above, 167 RxNorm Dose Form concepts were
programmatically updated for this release during the content refresh. The
additional updates comprised changes to 12 MoA concept names during manual
reorganization of the MoA hierarchy.
-----------------------------------------------------------------
February 2009 NDF-RT (version name 2009.02.10)
This release reflects content in a new NDF-RT namespace, which is intended
to be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives. For more
information, please refer to the release notes from the December 2008/January
2009 version (2009.01.13, below), as well as the document Changes in NDF-RT
Public Edition.pdf, included with these release files.
This release of NDF-RT Public Edition contains 10 new concepts: 2 added to
the EXT hierarchy, 3 added to the MoA hierarchy, and 5 added to the PE
hierarchy.
39,140 total concepts
10 new concepts
0 changed concepts
0 concepts removed
-----------------------------------------------------------------
December 2008/January 2009 NDF-RT (version name 2009.01.13)
This release reflects content in a new NDF-RT namespace, which is intended to
be the "next generation" of NDF-RT, comprising a multi-namespace approach
that will restore focus on orderable clinical drugs, ingredients, and
descriptive classifications. It will also support clinical decision support,
quality of care research, and FDA SPL drug labeling initiatives.
The central content of NDF-RT now consists of core medication reference
terminology via NDF and NLM Daily Med updates; salient reference concept
hierarchies; and description logic-based drug & ingredient classification.
External content derived from other terminology sources will be integrated
and maintained via linkages, as opposed to direct incorporation into NDF-RT.
The new iteration of NDF-RT was created by removing and reinserting selected
concepts and attributes from the November 2008 version of NDF-RT
[Public Edition]. Some of the information removed will no longer be
maintained, and some will be maintained elsewhere. For example, VA Drug
Interaction concepts, previously maintained in NDF-RT and withheld from the
NDF-RT Public Edition, were reinserted for and are being included in this new
public edition. Orderable supply concepts (those beginning with XA*) and
their descendants, NDC-level concepts, and several obsolete VA class concepts
were removed. The following list is a summary of the additions and deletions:
TOTAL CONCEPTS IN PREVIOUS VERSION (2008.11.11.8AA): 136054
NDC concepts removed: 95368
Orderable supply (members of XA* classes) concepts removed: 4525
Obsolete drug class concepts removed: 2
VA Drug Interaction concepts restored: 2965
New concepts added for current version: 6
TOTAL CONCEPTS IN CURRENT VERSION (2009.01.13.8AB): 39130
The 6 new concepts added to this release include 3 added to the EXT
hierarchy, 2 added to the PE hierarchy, and 1 added to the MoA
hierarchy.
In addition to the removal/restoration of concepts mentioned above, this new
version contains a number of changes involving properties and associations,
and several corresponding qualifiers. For more information, please refer to
the document, Changes in NDF-RT Public Edition.pdf, included with these
release files.
-----------------------------------------------------------------
November 2008 NDF-RT (version name 2008.11.11)
This release of NDF-RT Public Edition contains 3 new concepts: 2 added to the
EXT hierarchy, and 1 added to the MoA hierarchy.
136,054 total concepts
3 new concepts
0 changed concepts
0 concepts removed
-----------------------------------------------------------------
October 2008 NDF-RT (version name 2008.10.14)
This release of NDF-RT Public Edition contains no changes from the previous
version.
136,051 total concepts
0 new concepts
0 changed concepts
0 concepts removed
-----------------------------------------------------------------
August/September 2008 NDF-RT (version name 2008.09.09)
This release of NDF-RT Public Edition contains 69 new concepts: 51 added to
the EXT hierarchy, 5 added to the PE hierarchy, and 13 added to the MoA
hierarchy.
The changed concepts count this month is due to 8 concept name changes:
Bile-acid Binding Resin [EXT] was changed to Bile Acid Binding Resin [EXT];
Interleukin 1 Receptor Antagonist [EXT] was changed to Interleukin-1 Receptor
Antagonist [EXT]; Interleukin 2 Receptor Blocking Antibody [EXT] was changed
to Interleukin-2 Receptor Blocking Antibody [EXT]; Interleukin 2
Receptor-directed Cytotoxin [EXT] was changed to Interleukin-2
Receptor-directed Cytotoxin [EXT]; Serotonin 1b and 1d Receptor Agonist [EXT]
was changed to Serotonin-1b and Serotonin-1d Receptor Agonist [EXT];
Serotonin 3 Receptor Antagonist [EXT] was changed to Serotonin-3 Receptor
Antagonist [EXT]; Serotonin 4 Receptor Antagonist [EXT] was changed to
Serotonin-4 Receptor Antagonist [EXT]; and Thyroid Peroxidase Inhibitors
[MoA] was changed to Iodide Peroxidase Inhibitors [MoA].
136,051 total concepts
69 new concepts
8 changed concepts
0 concepts removed
-----------------------------------------------------------------
July 2008 NDF-RT (version name 2008.07.08)
This release of NDF-RT Public Edition contains 85 new concepts: 67 added to
the EXT hierarchy, 4 added to the PE hierarchy, and 14 added to the MoA
hierarchy.
The changed concepts count this month is due to 8 concept name changes:
Corticotropin Releasing Hormone Alteration [PE] was changed to Corticotropin
Releasing Hormone Alteration [PE]; Decreased Folic Acid Modification [PE]
was changed to Decreased Folic Acid Modification [PE] to strip out extra
spaces in the concept name; Decreased Vitamin Uptake and Modification [PE]
was changed to Decreased Vitamin Uptake and Modification [PE], also to remove
extra spaces; GI Bulking Activity [MoA] was changed to Stool Bulking Activity
[MoA]; Hydrogen Ion Scavenging [MoA] was changed to Alkalinizing Activity
[MoA]; Neurokinin 1 Antagonist [MoA] and Sulfate Donor [MoA] were both made
plural; and Surfactants [MoA] was changed to Surfactant Activity [MoA].
The large removed concepts count this month is due to the removal of the
Biologic Structures of Recipient [Genomics] hierarchy, which will no longer
be included in the Public Edition of NDF-RT going forward.
135,982 total concepts
85 new concepts
8 changed concepts
127 concepts removed
-----------------------------------------------------------------
June 2008 NDF-RT (version name 2008.06.10)
This release of NDF-RT Public Edition contains 25 new concepts: 19 added to
the EXT hierarchy, 1 added to the PE hierarchy, and 5 added to the MoA
hierarchy.
The changed concepts count this month is due to 4 concept name changes: H1
Receptor Antagonist [EXT] was changed to Histamine-1 Receptor Antagonist
[EXT]; H1 Receptor Inhibitor [EXT] was changed to Histamine-1 Receptor
Inhibitor [EXT]; the [PE] tag was added to Peripheral Nervous System Activity
Alteration; and TNF Blocker [EXT] was changed to Tumor Necrosis Factor
Blocker [EXT].
136,024 total concepts
25 new concepts
4 changed concepts
0 concepts removed
-----------------------------------------------------------------
May 2008 NDF-RT (version name 2008.05.13)
This release of NDF-RT Public Edition contains 77 new concepts: 44 added to
the EXT hierarchy, 13 added to the PE hierarchy, 18 added to the MoA
hierarchy, and 2 added to the Chemical/Ingredient hierarchy.
Part of the large new concepts count is due to a reorganization of the
Nervous System PE hierarchy. The changed concepts count this month is due to
4 concept name changes: Chemical Structures for Pharmacologic Classification
[Chemical/Ingredient] was changed to Chemical Classes for Pharmacologic
Classification [Chemical/Ingredient]; Neurological & Neuromuscular System
Activity Alteration [PE] was changed to Nervous System Activity Alteration
[PE]; NMDA Receptor Antagonist [MoA] was made plural; and Striated Muscle
Alteration [PE] was changed to Striated Muscle Metabolic Alteration [PE].
135,999 total concepts
77 new concepts
4 changed concepts
0 concepts removed
-----------------------------------------------------------------
April 2008 NDF-RT (version name 2008.04.08)
This release of NDF-RT Public Edition contains 10 new concepts: 24 added to
the EXT hierarchy, 7 added to the PE hierarchy, and 4 added to the MoA
hierarchy.
The changed concepts count this month is due to two concept name changes. The
old concept name Alcohol Dehyrogenase Inhibitors [MoA] was changed to include
"Dehydrogenase", the correct spelling. The concept Angiotensin-Converting
Enzyme Inhibitors [MoA] was changed to make "-Converting" lowercase for
consistency with other hyphenated NDF-RT concept names.
135,922 total concepts
35 new concepts
2 changed concepts
0 concepts removed
-----------------------------------------------------------------
March 2008 NDF-RT (version name 2008.03.11)
This release of NDF-RT Public Edition contains 10 new concepts: 8 added to
the EXT hierarchy, and 2 added to the MoA hierarchy.
The changed concepts count this month is due to concept name changes.
Instances of the acronym "GNRH" in 4 existing concept names in the PE
hierarchy were changed to "GnRH". In addition, the following changes to EXT
concept names were made, with the former concept names retained as synonyms:
Angiotensin 2 Receptor Blocker [EXT], Phosphodiesterase 3 Inhibitor [EXT],
and Phosphodiesterase 5 Inhibitor [EXT] were renamed to include Roman
numerals, to replicate the original pharmacologic class requested phrases;
Greek letters in the concept names Interferon Alpha [EXT] and Interferon
Gamma [EXT] were lowercased; and GnRH Secretion Inhibitor [EXT] was changed
to reflect the fully-specified name Gonadotropin Releasing Hormone Secretion
Inhibitor [EXT].
135,887 total concepts
10 new concepts
12 changed concepts
0 concepts removed
-----------------------------------------------------------------
February 2008 NDF-RT (version name 2008.02.12)
This release of NDF-RT Public Edition contains 41 new concepts: 13 added to
the EXT hierarchy, 11 added to the MoA hierarchy, and 17 added to the PE
hierarchy.
The changed concepts count is due to subtree reorganization under the new
concept Autonomic Nervous System Activity Alteration [PE]. In addition to
this hierarchy reorganization, a second parent was given to any legacy
neurotransmitter-specific sympathetic/parasympathetic activity concepts in
the new subtree. Finally, a number of concept names containing
"Norepinepherine" were changed to reflect the correct spelling.
135,877 total concepts
41 new concepts
37 changed concepts
2 concepts removed
-----------------------------------------------------------------
January 2008 NDF-RT (version name 2008.01.08)
This release of NDF-RT Public Edition contains changes reflecting decisions
made at the November 2007 SPL IEP face-to-face meeting. The former Additional
FDA Pharmacologic Classes for SPL hierarchy has been renamed to "External
Pharmacologic Classes", and now contains new concepts whose names replicate
each pharmacologic class string received. These concepts are mapped via role
relationships to appropriate MoA, PE, or Chemical/Ingredient concepts. All
concepts in this hierarchy have the tag [EXT] appended to their names,
replacing the former [FDA SPL] tag. In addition to new concepts created
manually in this hierarchy to reflect recent SPL IEP decisions, 61 concepts
were added programmatically from former FDA_SPL_Name property values that
existed for those NDF-RT concepts considered to be one-to-one maps to SPL
pharmacologic class phrases. These EXT concept names exactly replicate the
former FDA_SPL_Name property values. All existing FDA_SPL_Name property
values were then removed, and as this property will no longer be used, the
property type has been removed entirely from NDF-RT.
In addition to these 61 concepts added programmatically, there were 72 new
concepts added to the EXT hierarchy based on submissions from the
Antimicrobial/Transplant/Hematology FDA list. Other new concepts included 6
added to the Chemical/Ingredient hierarchy, 5 added to the PE hierarchy, and
11 added to the MoA hierarchy.
The changed concepts count is due to 14 MoA concepts, which were renamed for
consistency to include "Activity" instead of "Agents", "Preparations", or
"Scavengers", and one concept whose former name contained an incorrect
spelling. Additionally, 29 existing concepts in the EXT (formerly Additional
FDA Pharmacologic Classes for SPL) hierarchy were renamed, removing the
[FDA SPL] tag and adding the new [EXT] tag.
The concept Influenza Neuraminidase Inhibitors [MoA] was retired. The
newly-created concept Influenza Neuraminidase Inhibitor [EXT] retains this
former concept's NUI.
135,838 total concepts
145 new concepts
43 changed concepts
1 concept removed
-----------------------------------------------------------------
November 2007 NDF-RT (version name 2007.11.13)
This release of NDF-RT Public Edition contains 11 new concepts: 4 added in
the Additional FDA Pharmacologic Classes for SPL list, 6 added to the MoA
hierarchy, and 1 added to the Chemical/Ingredient hierarchy.
The changed concepts count is due to two renamed MoA concepts, Tumor Necrosis
Factor Alpha Receptor Blocking Activity [MoA], and Tumor Necrosis Factor
Beta Receptor Blocking Activity [MoA].
135,684 total concepts
11 new concepts
2 changed concepts
0 concepts removed
-----------------------------------------------------------------
October 2007 NDF-RT (version name 2007.10.09)
This release of NDF-RT Public Edition contains 17 new concepts: 8 added in
the Additional FDA Pharmacologic Classes for SPL list, 1 added to
Supplementary Chemicals [Chemical/Ingredient], 1 added to the PE hierarchy,
5 added to the MoA hierarchy, and 2 added to the Chemical/Ingredient
hierarchy.
An official NDF-RT SPL IEP decision was made to add a second FDA_SPL_Name,
beta-Adrenergic Receptor Inhibitor, to the concept Adrenergic
beta-Antagonists [MoA], which was mapped to both the New Products pharm.
class phrase with the same string and the Cardiac/Renal submission
beta-adrenergic blocker. Going forward, this approach will ONLY be used when
the FDA_SPL_Name values are true synonyms.
135,673 total concepts
17 new concepts
0 changed concepts
0 concepts removed
-----------------------------------------------------------------
August/September 2007 NDF-RT (version name 2007.08.31)
This full release of NDF-RT Public Edition contains the new "Additional FDA
Pharmacologic Classes for SPL" list under "Pharmaceutical Preparations". Its
16 assigned children were created in response to requests for concepts to
support the FDA Structured Product Labeling (SPL) initiative. Concepts in
this group represent specific requests for SPL Pharmacologic Class phrases
that can not be represented by a single new or existing MOA, PE or CS NDF-RT
concept. This includes phrases that represent therapeutic intent as defined
by the FDA SPL initiative, as well as those represented by the concatenation
of multiple NDF-RT concepts, and in rare cases ideas that did not fit
elsewhere within NDF-RT. None of the concepts in this new group are listed in
the MOA, PE or CS SPL files published separately but many have defining role
relationships to one or more MOA, PE and CS concepts.
The changed concepts count includes concepts changed for remodeling of the
Nucleic Acid Synthesis Inhibitors [MoA], Protease Inhibitors [MoA], and
Kinase Inhibitors [MoA] subtrees, as well as concepts affected by new
FDA_SPL_Name algorithm, and two concepts renamed due to misspellings.
Fms-like tyrosine kinase (FLT) Inhibitors [MoA] was removed after
determining that it was not used as a role value for NDF-RT drug modeling.
135,656 total concepts
17 new concepts
78 changed concepts
1 concept removed
-----------------------------------------------------------------
July 2007 NDF-RT (version name 2007.07.10)
This Full release of NDF-RT Public Edition contains no added concepts based
on FDA submissions for SPL. Changes in this version of NDF-RT occurred solely
due to a few changes and 85 additional mappings of NDF-RT Disease concepts
that already had at least one existing SNOMED CT mapping. None of these were
on the current SPL Problem List (Jan. 2007). These changes resulted in the
creation of at least one additional map from that Disease concept to a
SNOMED CT concept on the SPL Problem List. A map (recorded as a property on
the concept) to a SNOMED CT concept on the SPL Problem List will now be
called the SPL_Problem_List_Mapping_ID. In addition, the existing SNOMED_ID
property was renamed to SNOMED_Mapping_ID. This final change resulted in the
large "changed concept" count.
135,640 total concepts
0 new concepts
2478 changed concepts
-----------------------------------------------------------------
June 2007 NDF-RT (version name 2007.06.12)
This Full release of NDF-RT Public Edition contains changes derived from SPL
Pharmacologic Class requirements plus changes derived from a
re-synchronization of the Chemical/Ingredient hierarchy with the current
version of MeSH (2007).
135,640 total current concepts
324 new concepts
33 changed concepts
21 deprecated concepts (reflects semantic duplicates noted either
due to formal SPL decisions or MeSH refresh QA process. Prior
meanings and NUIs of these concepts are attributed to existing
NDF-RT concepts.)
A substantial reduction in the number of synonyms is reflected in this
release due to the improved accuracy of synonym assignment based on UMLS
Metathesaurus. Removed synonyms were all from the Chemical/Ingredient
hierarchy. Chemicals and Ingredients concepts were derived from 2007 ASCII
MeSH files.
-----------------------------------------------------------------
May 2007 NDF-RT (version name 2007.05.08)
Starting with the May 2007 release a new property has been created:
FDA_SPL_Name. This property will only be added to concepts when there is
requirement for a concept representation (IE: a term name) preferred for SPL
use that is not the existing "preferred name" for the concept. The value
of the FDA_SPL_Name property may be an existing synonym, or it may be a new
term representation. If it is new, it will only be additionally added as a
synonym for concepts NOT derived from MeSH. This was done to keep synonyms
algorithmically consistent with the UMLS MeSH synonym list for that concept
(as noted above.) Only concepts requiring these additions will carry this
property. This means that any SPL user must determine if that property exists
for a concept and use the value as the concept preferred name.
This Full release of NDF-RT Public Edition contains only a few changes
modeled and approved by the ICCB committee.
135,337 total current concepts
6 new concepts
1 changed concept
1 retired concept
Chemicals and ingredient concepts were derived from MeSH 2006 (2006_05_01)
-----------------------------------------------------------------
April 2007 NDF-RT (version name 2007.04.10)
This Full release of NDF-RT Public Edition contains only a few changes
modeled and approved by the ICCB committee.
135,332 total current concepts
10 new concepts
1 changed concept
1 retired concept
Chemicals and ingredient concepts were derived from MeSH 2006 (2006_05_01)
-----------------------------------------------------
March 2007 NDF-RT (version name 2007.03.13)
As of the March, 2007, the provision of NDF-RT content outside the VA system
will not include elements deemed only of value to internal VA operations.
This "extract" will be known as the NDF-RT Public Edition and will contain
all of the core NDF-RT concepts that existed in previous releases and all
concept NUIs will remain unchanged. In essence the Public Edition only
removes selected VA-specific properties, qualifiers, associations and a few
Kinds that represented information required for unique internal VA
activities. All Roles remain unchanged.
These changes are expected to have no impact on non-VA use of the NDF-RT.
Listed below are the changes implemented beginning with this release.
***********************************************
**ELEMENTS PRESERVED IN NDF-RT PUBLIC EDITION**
***********************************************
<Selected KINDS>
NDF_KIND {formerly DRUG_KIND}
INGREDIENT_KIND
MECHANISM_OF_ACTION_KIND
PHYSIOLOGIC_EFFECT_KIND
PHARMACOKINETICS_KIND
DISEASE_KIND
RECIP_STRUCTURES_KIND
RXNORM_DOSE_FORM_KIND
<All ROLES> Source -> Target
has_Ingredient NDF_KIND --> INGREDIENT_KIND
CI_ChemClass NDF_KIND --> INGREDIENT_KIND
metabolized_by NDF_KIND --> INGREDIENT_KIND
has_active_metabolites NDF_KIND --> INGREDIENT_KIND
effect_may_be_inhibited_by NDF_KIND --> NDF_KIND
metabolized_by_recip_structure NDF_KIND --> RECIP_STRUCTURES_KIND
gene_encodes_for RECIP_STRUCTURES_KIND --> INGREDIENT_KIND
gene_has_variant RECIP_STRUCTURES_KIND --> RECIP_STRUCTURES_KIND
gene_encodes_for_enzyme RECIP_STRUCTURES_KIND --> RECIP_STRUCTURES_KIND
has_MoA NDF_KIND --> MECHANISM_OF_ACTION_KIND
CI_MoA NDF_KIND --> MECHANISM_OF_ACTION_KIND
has_PE NDF_KIND --> PHYSIOLOGIC_EFFECT_KIND
CI_PE NDF_KIND --> PHYSIOLOGIC_EFFECT_KIND
has_PK NDF_KIND --> PHARMACOKINETICS_KIND
site_of_metabolism NDF_KIND --> PHARMACOKINETICS_KIND
may_treat NDF_KIND --> DISEASE_KIND
may_prevent NDF_KIND --> DISEASE_KIND
may_diagnose NDF_KIND --> DISEASE_KIND
induces NDF_KIND --> DISEASE_KIND
CI_with NDF_KIND --> DISEASE_KIND
has_DoseForm NDF_KIND --> RXNORM_DOSE_FORM_KIND
<Selected ASSOCIATIONS>
Heading_Mapped_To INGREDIENT_KIND --> INGREDIENT_KIND
VA_Product_Component NDF_KIND --> NDF_KIND
VA_Secondary_Drug_Class NDF_KIND --> NDF_KIND
<Selected ASSOCIATION QUALIFIERS>
VA_Strength
VA_Unit
<Selected PROPERTIES>
NUI
Display_Name
Synonym
Level
Status
Status_Change_Date
Review_Status
MeSH_Name
MeSH_UI
Included_MeSH_UIs
MeSH_Definition
MeSH_Pharmacologic_Action
NCI_Preferred_Term
RxNorm_CUI
RxNorm_Code
RxNorm_Name
RxNorm_Preferred_Translation_Term
SNOMED_ID
UNII
UMLS_CUI
UMLS_Semantic_Type
UMLS_Preferred_Translation_Term
VUID
VA_Class_Description
VA_Class_Code
VA_Class_Type
VA_CS_Federal_Schedule
VA_Manufacturer_Code
VA_National_Formulary_Name
VA_NDC
VA_NDF_Type
VA_Product_Code
VA_Package_Code
VA_Print_Name
VA_RxOtc_Indicator
VA_Strength
VA_Trade_Name
VA_Units
VA_UPN
<Selected PROPERTY QUALIFIERS>
Date
Status
VUID
***********************************************************
**VA-SPECIFIC ELEMENTS REMOVED FROM NDF-RT PUBLIC EDITION**
***********************************************************
<Selected KINDS>
EXTERNAL_REFERENCE_KIND
VA_DISPENSE_UNITS_KIND
VA_DOSE_FORMS_KIND
VA_DRUG_INTERACTION_KIND
VA_DRUG_MANUFACTURER_KIND
VA_DRUG_UNIT_KIND
VA_NATIONAL_FORMULARY_RESTRICTION_KIND
VA_PACKAGE_SIZE_KIND
VA_PACKAGE_TYPE_KIND
VA_ROUTE_OF_ADMINISTRATION_KIND
<Selected ASSOCIATIONS>
External_Dispense_Unit
External_Dose_Form
External_Package_Size
External_Package_Type
External_ROA
VA_Dispense_Units
VA_Dose_Form
VA_Dose_Form_Units
VA_Drug_Manufacturer
VA_Ingredient_1
VA_Ingredient_2
VA_National_Formulary_Restriction
VA_Package_Size
VA_Package_Type
VA_ROA
<Selected ASSOCIATION QUALIFIERS>
FILE
IEN
PACKAGE
<Selected PROPERTIES>
Search_Name
Last_Reviewed
Reviewed_By
Comment
Alert
VA_Abbreviation
VA_Discontinue
VA_Dispense_Units_Per_Dose
VA_Dose_Form_Print_Name
VA_Drug_Identifier
VA_DSS_Number
VA_Exclude_Drug_Interaction_Check
VA_File
VA_IvFlag
VA_Max_Cumulative_Dose
VA_Max_Daily_Dose
VA_Max_Single_Dose
VA_Min_Daily_Dose
VA_Min_Single_Dose
VA_Nationally_Entered
VA_National_Formulary_Indicator
VA_NDT_XML
VA_Package_Use
VA_Product_Identifier
VA_Severity
VA_Single_or_Multi_Source_Product
VA_Total_Indexes
VA_Transaction_History
VA_Transmit_to_CMOP
VA_User_Lock
VA_Workflow_Comment
VA_Workflow_Status
<Selected PROPERTY QUALIFIERS>
User Name
VA_Class_Description_Line
VA_File
VA_IEN
VA_PACKAGE
NDF-RT Public Edition Release notes
Created on 3/23/07 - 1 -